This website uses third-party profiling cookies to provide services in line with the preferences you reveal while browsing the Website. By continuing to browse this Website, you consent to the use of these cookies. If you want to object such processing, please read the instructions described in our Cookie Policy.

David Chiswell


Chiswell, 65, was head of one of Britain’s most successful life sciences companies, Cambridge Antibody Technology. He went on to found and chair Kymab, which develops drugs with the help of mice genetically engineered to produce human antibodies. He is now adviser to the firm, which has had $100m of investment from backers such as Shenzhen Hepalink Pharmaceutical.

Request a Test Drive, a Quote or More Information